Spherix Announces 2008 Financial Results( BETHESDA Md. March 30 /- Spherix Inco...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Spherix Announces 2008 Financial Results
Date:3/30/2009
BETHESDA, Md., March 30 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the year ended December 31, 2008.
Recent Company Highlights
- Biospherics
- Naturlose(R) Phase 3 clinical trial investigating efficacy as a treatment for Type 2 diabetes continues on schedule; completion expected in mid-2010
- Interim data results expected in third quarter of 2009
- Completion of the related Phase 2 Dose Range trial expected in 2009
- Peer-reviewed publication of new results from animal studies
- Spherix Consulting
- Revenue from health sciences consulting services has grown every quarter since its start in July 2007
- Additional consulting staff hired to handle increased demand
"The next few months will be an exciting time for Spherix and its shareholders," stated Dr. Claire L. Kruger, CEO of Spherix. "The Company anticipates sharing interim data in the fall from its ongoing Phase 3 clinical trial investigating the efficacy of Naturlose as a novel treatment for Type 2 diabetes. I am pleased to report that Spherix will be holding its first earnings webcast on April 2, during which we will provide our shareholders and other interested parties with additional information and updates on both the Biospherics and Spherix Consulting subsidiaries."
Financial Results for the Year Ended 2008
'/>"/>
| SOURCE Spherix Incorporated Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
Breaking Biology Technology:Biomatrica Launches SampleWare 3.1 2Biomatrica Launches SampleWare 3.1 3Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2
[0] Biomatrica Launches SampleWare 3.1[0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors[0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices[0] Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease
Other Biology Technology:Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 2Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 3Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 4Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 5Plurality Completes R&D of its HAL-256 Multicore Processor 2NIU Seeks OK for New Proton Cancer Treatment and Research Center 2NIU Seeks OK for New Proton Cancer Treatment and Research Center 3
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 1BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 2BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 3BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 4New Drug Promising Against Rheumatoid Arthritis 50263 1New Drug Promising Against Rheumatoid Arthritis 50263 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 1Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 3
Other Biology News:Brown University and Women & Infants Hospital expand national children's study to Bristol County 2Brown University and Women & Infants Hospital expand national children's study to Bristol County 3Brown University and Women & Infants Hospital expand national children's study to Bristol County 4The structure of the Mre11 protein bound to DNA 2The structure of the Mre11 protein bound to DNA 3The structure of the Mre11 protein bound to DNA 4The structure of the Mre11 protein bound to DNA 5The structure of the Mre11 protein bound to DNA 6UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 2UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |